Aduro BioTech (NASDAQ: ADRO) recently received a number of ratings updates from brokerages and research firms: 10/14/2015 – Aduro BioTech was upgraded by analysts at Zacks from a “sell” rating to a “hold” rating. According to Zacks, “Aduro Biotech, Inc. is an immunotherapy company. The Company develops technology and vaccines for the treatment of cancer […]
